Dr. Friedlaender has a professional interest in treating tumors and pathological fractures, metastatic disease to the bone, fracture non unions and bone cancer. He also serves as a professor of orthopedics and pathology at Yale. In addition to his practice, Dr. Friedlaender has served on the editorial boards of several journals, including The Journal of Bone and Joint Surgery, Clinical Orthopaedics and Related Research and Spine.
During his career, Dr. Friedlaender has earned several awards for his research. Among his recognitions, he has earned the Kappa Delta Award from AAOS and the Nicholas Andry Award from the Association of Bone and Joint Surgeons. He has also served as director of BioMimetic Therapeutics and has served as a chairman of the orthopedic scientific advisory board of Forbes.
Dr. Friedlaender earned his medical degree from the University of Michigan in Ann Arbor and completed his residency at Newington (Conn.) Children’s Hospital, focusing on pediatric orthopedics. His additional training includes a residency in orthopedic surgery at Yale New Haven (Conn.) Hospital.
In addition to his initial medical training, Dr. Friedlaender has completed the Berg-Sloat Traveling Fellowship in Sweden and England focusing on bone biology and tumor immunobiology. He has also completed fellowships in reproductive biology at the University of Michigan, musculoskeletal oncology at Massachusetts General Hospital in Boston and a research fellowship in oncology and immunobiology at Yale University School of Medicine.
Learn more about Dr. Gary E. Friedlaender.
Read other coverage on orthopedic and spine industry leaders:
– Orthopedic and Spine Industry Leader to Know: Dr. Frederick M. Azar of UT-Campbell Clinic
